Enhanced Genomics has appointed Katerina Leftheris to its board of directors, strengthening the company’s leadership as it expands its internal therapeutics pipeline using its 3D multi-omics platform.

The Cambridge-based biotechnology company applies multi-dimensional genomics to rapidly identify high-confidence, genetically validated drug targets for common and complex diseases. Leftheris brings over 30 years of experience in drug discovery and development across large pharmaceutical and biotechnology companies, including Bristol Myers Squibb, Celgene, and Pliant Therapeutics. Her experience spans advancing compounds from preclinical discovery into clinical development, medicinal chemistry, and precision therapeutics.

Dietrich Stephan, executive chair of Enhanced Genomics, said Leftheris’s appointment supports the company’s growth strategy.

He said: “I am thrilled to welcome Katerina as the newest member of our Board. Her exceptional expertise in therapeutics discovery and clinical drug development will be an invaluable asset as we progress our ambitious plans to drive the next era of precision therapeutics development.”

Leftheris has also held leadership roles at machine learning-based drug development companies and currently serves on multiple boards and scientific advisory committees for biotechnology companies. She has been elected 2026 vice chair for the Medicinal Chemistry Division and member of the Committee on Science for the American Chemical Society.

Commenting on her appointment, Leftheris said she was attracted by the company’s approach to precision therapeutics.

She said: “Building on decades of genomics research, Enhanced’s 3D multi-omics platform has the potential to define causal biology, enabling the identification of high-confidence, first-in-class therapeutic targets, to drive the development of truly disease-modifying therapies. I look forward to supporting the executive team to advance the development of the Company’s pipeline of effective precision therapies for genetically complex diseases.”

Leftheris will advise Enhanced’s executive team on advancing its therapeutics pipeline, leveraging the GenLink platform and cell type-specific atlas to identify novel disease targets from genome-wide variants and support faster, higher-confidence drug discovery.